KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Rigel Pharmaceuticals (RIGL) Cost of Revenue (2018 - 2025)

Historic Cost of Revenue for Rigel Pharmaceuticals (RIGL) over the last 8 years, with Q3 2025 value amounting to $4.8 million.

  • Rigel Pharmaceuticals' Cost of Revenue fell 4078.0% to $4.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $19.5 million, marking a year-over-year increase of 1686.09%. This contributed to the annual value of $18.6 million for FY2024, which is 16226.44% up from last year.
  • According to the latest figures from Q3 2025, Rigel Pharmaceuticals' Cost of Revenue is $4.8 million, which was down 4078.0% from $4.5 million recorded in Q2 2025.
  • In the past 5 years, Rigel Pharmaceuticals' Cost of Revenue registered a high of $8.0 million during Q3 2024, and its lowest value of $121000.0 during Q1 2022.
  • Over the past 5 years, Rigel Pharmaceuticals' median Cost of Revenue value was $1.1 million (recorded in 2023), while the average stood at $2.2 million.
  • Its Cost of Revenue has fluctuated over the past 5 years, first crashed by 6170.89% in 2022, then soared by 100818.71% in 2023.
  • Rigel Pharmaceuticals' Cost of Revenue (Quarter) stood at $487000.0 in 2021, then decreased by 29.77% to $342000.0 in 2022, then skyrocketed by 1008.19% to $3.8 million in 2023, then soared by 52.74% to $5.8 million in 2024, then dropped by 17.9% to $4.8 million in 2025.
  • Its Cost of Revenue stands at $4.8 million for Q3 2025, versus $4.5 million for Q2 2025 and $4.4 million for Q1 2025.